KR910000140A - 신장 질환 치료용 영양제제 - Google Patents
신장 질환 치료용 영양제제 Download PDFInfo
- Publication number
- KR910000140A KR910000140A KR1019900009129A KR900009129A KR910000140A KR 910000140 A KR910000140 A KR 910000140A KR 1019900009129 A KR1019900009129 A KR 1019900009129A KR 900009129 A KR900009129 A KR 900009129A KR 910000140 A KR910000140 A KR 910000140A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ketoisocaproate
- keto
- suspended
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000015872 dietary supplement Nutrition 0.000 title 1
- 208000017169 kidney disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 229960002898 threonine Drugs 0.000 claims 4
- 229960004799 tryptophan Drugs 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- SEGLGXWKMQWPCB-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1 SEGLGXWKMQWPCB-JEDNCBNOSA-N 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000015203 fruit juice Nutrition 0.000 claims 2
- 235000020905 low-protein-diet Nutrition 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 159000000001 potassium salts Chemical class 0.000 claims 2
- 229960004441 tyrosine Drugs 0.000 claims 2
- IUQCXXQQMQULHI-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O.NCCC[C@H](N)C(O)=O IUQCXXQQMQULHI-WCCKRBBISA-N 0.000 claims 1
- UMQFXFDTFNTJRK-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O.NCCC[C@H](N)C(O)=O UMQFXFDTFNTJRK-VWMHFEHESA-N 0.000 claims 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 신부전증으로 고생하는 환자에게 유효 영양 용량의 하기 성분을 하기 중량%로 포함하는 조성물을 장내 또는 비경구 투여함을 특징으로 하여 신부전증으로 고생하는 환자를 양양 치료하는 방법.L-오르니틴-α-케토이소발레레이트 20 내지 25%L-오르니틴-α=케토이소캐프로에이트 20 내지 25%L-리신-α-케토-β메틸발레레이트 20 내지 25%L-히스티딘-α-케토이소캐프로에이트 5 내지 9% α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1 내지 3%L-트립토판 0.1 내지 1%L-티로신 15 내지 20%L-트레오닌 3 내지 7%.
- 제1항에 있어서, 조성물을 저단백식이와 함께 투여하는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 수성 매질에 용해/현탁시키는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 향미제를 함유하는 수성 매질에 용해/현탁 시키는 방법.
- 제1항에 있어서, 조성물을 투여하기 전에 과일 쥬스에 용해/현탁시키는 방법.
- 신부전증으로 고생하는 환자에게 유효 영양 용량의 하기 성분을 하기 중량%로 포함하는 조성물을 장내 또는 비경구 투여함을 특징으로 하여 신부전증으로 고생하는 환자를 영양 치료하는 방법.L-오르티닌-α-케토이소발레레이트 20 내지 25%L-오르니틴-α-케토-메틸발레레이트 20 내지 25%L-리신-α-케토-케토이소캐프로에이트 20 내지 25%L-히스티딘-α-케토이소캐프로에이트 5 내지 9%-α-하이드록시-γ-메틸티로부티레이느의 칼슘염, 나트륨염 또는 칼륨염 1 내지 3%L-트립토판 0.1 내지 1%L-티로신 15 내지 20%L-트레오닌 3 내지 7%.
- 제6항에 있어서, 조성물을 저단백식이와 함께 투여는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 수성 매질에 용해/현탁시키는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 향미제를 함유하는 수성 매질에 용해/현탁 시키는 방법.
- 제6항에 있어서, 조성물을 투여하기 전에 과일 쥬스에 용해/현탁시키는 방법.
- 하기 중량%의 하기 성분의 혼합물로 이루어진 조성물.L-오르티닌-α-케토이소발레레이트 21 내지 25%L-오르니틴-α-케토이소캐프로에이트 21 내지 25%L-리신-α-케토-β-메틸발레레이트 21 내지 25%L-히스티딘-α-케토이소캐프로에이트 6 내지 8% α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1.5 내지 2.5%L-트립토판 0.2 내지 0.75%L-티로신 16내지 19%L-트레오닌 4 내지 6%.
- 하기 중량%의 하기 성분의 혼합물로 이루어진 조성물.L-오르티닌-α-케토이소발레레이트 21 내지 24%L-오르니틴-α-케토-β-메틸발레레이트 21 내지 24%L-리신-α-케토-케토이소케프로에이트 21 내지 24%L-히스티딘-α-케토이소캐프로에이트 6 내지 8%-α-하이드록시-γ-메틸티로부티레이트의 칼슘염, 나트륨염 또는 칼륨염 1.5 내지 25%L-트립토판 0.2 내지 2.5%L-티로신 0.2내지 10.75%L-트레오닌 4 내지 6%.※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/369,163 US4957938A (en) | 1989-06-21 | 1989-06-21 | Nutritional formulation for the treatment of renal disease |
| US369163 | 2006-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR910000140A true KR910000140A (ko) | 1991-01-29 |
Family
ID=23454347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019900009129A Withdrawn KR910000140A (ko) | 1989-06-21 | 1990-06-21 | 신장 질환 치료용 영양제제 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4957938A (ko) |
| EP (1) | EP0405295B1 (ko) |
| JP (1) | JPH0331211A (ko) |
| KR (1) | KR910000140A (ko) |
| AT (1) | ATE91392T1 (ko) |
| AU (1) | AU627041B2 (ko) |
| CA (1) | CA2019472A1 (ko) |
| DE (1) | DE69002201T2 (ko) |
| ES (1) | ES2058687T3 (ko) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| CA2116684A1 (en) * | 1991-09-27 | 1993-04-01 | Robert G. Kilbourn | Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies |
| US5234696A (en) * | 1991-12-27 | 1993-08-10 | Abbott Laboratories | Method of producing tablets, tablets produced thereby, and method of treatment using same |
| US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US6287620B1 (en) * | 1994-10-07 | 2001-09-11 | Firmenich Sa | Flavor enhancing methods |
| AUPN115095A0 (en) * | 1995-02-15 | 1995-03-09 | Butt, Henry Lawrence | Analysis of and compositions and methods for the treatment of disease |
| FR2775901B1 (fr) * | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
| US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
| WO1999051252A1 (en) * | 1998-04-03 | 1999-10-14 | The Daily Wellness Company | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| US6288116B1 (en) | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
| US6605115B1 (en) * | 1999-06-05 | 2003-08-12 | Board Of Trustees Of The Leland Stanford Junior University | Method and composition for inhibiting cardiovascular cell proliferation |
| US7696219B2 (en) * | 2000-09-27 | 2010-04-13 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiences in renal patients |
| US6995166B1 (en) | 2000-09-27 | 2006-02-07 | Everett Laboratories, Inc. | Method and composition for supplementation of nutritional deficiencies in renal patients |
| US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
| US6989164B2 (en) * | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
| FR2822704B1 (fr) * | 2001-03-29 | 2005-02-18 | Chiesi Sa | Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments |
| JP2004527529A (ja) * | 2001-04-04 | 2004-09-09 | クリティカル セラピューティックス インコーポレイテッド | 急性腎不全を予防するための方法 |
| ITTO20020672A1 (it) * | 2002-07-26 | 2004-01-26 | Medestea Res And Production S | Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale |
| CA2557814A1 (en) * | 2004-03-01 | 2005-09-15 | Lumen Therapeutics, Llc | Compositions and methods for treating diseases |
| ES2882278T3 (es) * | 2018-07-31 | 2021-12-01 | Evonik Operations Gmbh | Mezclas de cetoácidos de cadena ramificada (BCKA) y procedimiento para la producción de tales mezclas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1511302A (en) * | 1974-04-15 | 1978-05-17 | Univ Johns Hopkins | Pharmaceutical compositions comprising amino acid analogues |
| US4100293A (en) * | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US4320146A (en) * | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4296127A (en) * | 1979-04-18 | 1981-10-20 | The Johns Hopkins University | Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof |
| US4352814A (en) * | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4677121A (en) * | 1985-01-22 | 1987-06-30 | The Johns Hopkins University | Method of inhibiting muscle protein degradation |
| US4752619A (en) * | 1985-12-23 | 1988-06-21 | The Johns Hopkins University | Nutritional supplement for treatment of uremia |
| FR2615734B1 (fr) * | 1987-05-27 | 1989-12-01 | Synthelabo | Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie |
-
1989
- 1989-06-21 US US07/369,163 patent/US4957938A/en not_active Expired - Fee Related
-
1990
- 1990-06-19 ES ES90111519T patent/ES2058687T3/es not_active Expired - Lifetime
- 1990-06-19 DE DE90111519T patent/DE69002201T2/de not_active Expired - Fee Related
- 1990-06-19 AT AT90111519T patent/ATE91392T1/de not_active IP Right Cessation
- 1990-06-19 EP EP90111519A patent/EP0405295B1/en not_active Revoked
- 1990-06-20 AU AU57673/90A patent/AU627041B2/en not_active Ceased
- 1990-06-21 KR KR1019900009129A patent/KR910000140A/ko not_active Withdrawn
- 1990-06-21 JP JP2163958A patent/JPH0331211A/ja active Pending
- 1990-06-21 CA CA002019472A patent/CA2019472A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0405295A3 (en) | 1991-03-27 |
| DE69002201D1 (de) | 1993-08-19 |
| US4957938A (en) | 1990-09-18 |
| AU627041B2 (en) | 1992-08-13 |
| ES2058687T3 (es) | 1994-11-01 |
| EP0405295A2 (en) | 1991-01-02 |
| ATE91392T1 (de) | 1993-07-15 |
| AU5767390A (en) | 1991-01-03 |
| EP0405295B1 (en) | 1993-07-14 |
| JPH0331211A (ja) | 1991-02-12 |
| DE69002201T2 (de) | 1994-01-05 |
| CA2019472A1 (en) | 1990-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910000140A (ko) | 신장 질환 치료용 영양제제 | |
| Michaelsson | Zinc therapy in acrodermatitis enteropathica | |
| AU2002230270B2 (en) | Rehydration composition | |
| Bhan et al. | Clinical trials of improved oral rehydration salt formulations: a review | |
| Bollman et al. | The physiology of the impaired liver | |
| EP0007691B1 (en) | Compositions for use in decreasing appetite for calories as carbohydrates | |
| Ju et al. | Changes in total nitrogen content of some abdominal viscera in fasting and realimentation | |
| CA2778823A1 (en) | Treatments using citrulline | |
| Overman et al. | Studies on the Hemorrhagic Sweet Clover Disease: IX. The Effect of Diet and Vitamin K on the Hypopro-Thrombinemia Induced by 3, 3′-Methylenebis (4-Hydroxycoumarin) in the Rat, One Figure | |
| Locatelli et al. | Supplemented low-protein diet and once-weekly hemodialysis | |
| Di Girolamo et al. | Contraction and nutrition interaction promotes anabolism in cachectic muscle | |
| Larralde et al. | Scurvy in a 10‐month‐old boy | |
| Homsy et al. | Nutrition and autoimmunity: a review | |
| Chaitow | Amino acids in therapy: a guide to the therapeutic application of protein constituents | |
| Helal | Progressive effects of the interaction of sodium nitrite and sunset yellow on different physiological parameters in albino rats | |
| Gaull | Pathogenesis of maple-syrup-urine disease: observations during dietary management and treatment of coma by peritoneal dialysis | |
| Heraief et al. | The treatment of obesity by carbohydrate deprivation suppresses plasma tryptophan and its ratio to other large neutral amino acids | |
| Friedman et al. | Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis | |
| KR0178799B1 (ko) | 면역계 활성을 증가시키기 위한 약학 조성물 | |
| Standen et al. | Immunonutrition: an update | |
| Ungley | The pathogenesis of megaloblastic anaemias and the value of vitamin B12 | |
| Oke | Some aspects of the role of cyanogenic glycosides in nutrition | |
| Fisher et al. | Levels of histidine and histidine derivatives in breast muscle of protein-depleted and repleted adult cockerels | |
| Wood | Potassium bicarbonate supplementation and calcium metabolism in postmenopausal women: are we barking up the wrong tree? | |
| Boyd | Diet and drug toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19900621 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |